权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Application of Mucolytic Therapy in Patient-Derived Models of Pseudomyxoma Peritonei

粘液溶解疗法在腹膜假粘液瘤患者来源模型中的应用

基本信息

批准号：
9808331
负责人：
Mohammad Haroon Asif Choudry
金额：
$ 17.02万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-06-01 至 2021-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9808331
关键词：
Acetylcysteine Appendiceal Neoplasms Biological Models Bromelains Characteristics Clinical Colorectal Cancer Computer Simulation Cytotoxic agent Dimensions Disease Dose Drug Combinations Drug Targeting Environment Functional disorder Gel Goals Granulocyte-Macrophage Colony-Stimulating Factor Human In Vitro Incidence Institution Interleukin-3 International Intra-abdominal Longevity Malignant Neoplasms Malignant neoplasm of ovary Malignant neoplasm of pancreas Modeling Molecular Morbidity - disease rate Mucin-2 Staining Method Mucinous Mucinous Neoplasm Mucolytics Mucous body substance Mus Nature Neoplasm Metastasis Non obese Operative Surgical Procedures Organ Organoids Outcome Pathway interactions Patients Peritoneal Pharmaceutical Preparations Polymers Production Proteins Pseudomyxoma Peritonei Rare Diseases Research Role Safety Severe Combined Immunodeficiency Stem Cell Factor Therapeutic Therapeutic Intervention Transgenic Organisms Transplant Recipients Tumor Burden Tumor Tissue Xenograft procedure biomedical referral center cancer cell chemotherapy clinically relevant combinatorial cytotoxic cytotoxicity diabetic efficacy testing extracellular humanized mouse improved in vivo in vivo Model intraperitoneal neoplastic cell novel preclinical efficacy preclinical study tumor growth tumor xenograft

项目摘要

Abstract Pseudomyxoma peritonei (PMP), an insidious but lethal malignancy, refers to peritoneal metastases from mucinous appendix neoplasms (MAN). PMP is poorly responsive to systemic chemotherapy and frequently recurs despite aggressive and morbid locoregional surgical therapy. For low-grade PMP (LG-PMP), nearly all of the deleterious clinical consequences are related to compressive organ dysfunction from excessive production and intra-abdominal accumulation of paucicellular mucus (predominantly composed of mucin 2 [MUC2] protein). Conversely, high-grade PMP (HG-PMP) is more cellular and invasive, and the abundant extracellular mucus provides a protective environment for cancer cells to thrive. We hypothesize that reducing extracellular mucus accumulation will minimize compressive organ dysfunction by decreasing the mucinous tumor burden of PMP (especially LG-PMP) and improve the efficacy of chemotherapeutic or targeted drugs by removing the protective mucus barrier surrounding neoplastic cells (especially HG-PMP). In this proposal, we will test the efficacy of combinatorial mucolytic therapy, using bromelain (BR) + N-acetylcysteine (NAC), to dissolve extracellular mucus in clinically relevant in vitro and in vivo patient-derived models of LG- and HG-MAN/PMP. Successful outcome of the proposed studies will overcome a major hurdle for treating PMP, which is the mass-effect and cytoprotective-effect of abundant extracellular mucus. In addition, our proposed research provides a novel treatment dimension for PMP that may be applied to mucinous colorectal, pancreatic and ovarian cancers. Our proposal is feasible since we are a major referral center for the management of patients with PMP, the proposed drug combination effectively dissolves mucus in-silico, and we have developed in vitro and in vivo patient-derived models of MAN/PMP that are representative of the clinical disease.

摘要